"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
QUIXIN® (levofloxacin ophthalmic solution 0.5%) solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
|AEROBIC GRAM-POSITIVE MICROORGANISMS||AEROBIC GRAM-NEGATIVE MICROORGANISMS|
|Corynebacterium species*||Acinetobacter Iwoffii*|
|Staphylococcus aureus||Haemophilus influenzae|
|Staphylococcus epidermidis||Serratia marcescens*|
|Streptococcus (Groups C/F)|
|Streptococcus (Group G)|
|Viridans group streptococci|
|*Efficacy for this organism was studied in fewer than 10 infections.|
DOSAGE AND ADMINISTRATION
Days 1 and 2
Instill one to two drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.
Days 3 through 7
Instill one to two drops in the affected eye(s) every 4 hours while awake, up to 4 times per day.
QUIXIN® (levofloxacin ophthalmic solution) 0.5% is supplied in a white, low density polyethylene bottle with a controlled dropper tip and a tan, high density polyethylene cap in the following size: 5 mL fill in 5 cc container - NDC 68669-135-05
Store at 15° – 25°C (59° – 77°F).
Manufactured by: Santen Oy, P. O. Box 33, FIN-33721 Tampere, Finland. Licensed from: Daiichi Sankyo Co., Ltd., Tokyo, Japan. Marketed by: VISTAKON® Pharmaceuticals, LLC Jacksonville, FL 32256 USA. April 2006 Version. FDA revision date: 4/11/2005
Last reviewed on RxList: 12/18/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Quixin Information
Quixin - User Reviews
Quixin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get breaking medical news.